80S ribosome aminoacyl-tRNA binding site (80S A-site) (80S A-site)

The 80S ribosome aminoacyl-tRNA binding site (A-site) is the primary decoding center within the eukaryotic translation machinery, responsible for selecting and binding the correct aminoacyl-tRNA based on the mRNA codon sequence (Schmeing & Ramakrishnan, 2009, Nature). Located at the interface of the 40S and 60S subunits, the A-site plays a pivotal role in maintaining the fidelity of protein synthesis during the elongation phase (Melnikov et al., 2012, Nature Reviews Molecular Cell Biology). In recent years, this site has gained prominence as a therapeutic target for nonsense suppression therapy, which aims to treat genetic diseases like cystic fibrosis and Duchenne muscular dystrophy caused by premature termination codons (PTCs) (Keeling et al., 2014, Journal of Molecular Medicine). Drugs such as ataluren and ELX-02 bind to the 80S A-site to reduce the stringency of the decoding process, allowing the ribosome to incorporate a near-cognate tRNA at a PTC and continue translation to produce a full-length, functional protein (Welch et al., 2007, Nature; Crawford et al., 2020, Journal of Cystic Fibrosis). While promising, targeting the 80S A-site presents challenges, including the risk of inducing read-through at natural stop codons and potential toxicity arising from cross-reactivity with mitochondrial ribosomes, which share structural similarities with bacterial ribosomes (Hainrichson et al., 2008, Organic & Biomolecular Chemistry). This site is also a target for certain toxins and specialized antibiotics that can inhibit eukaryotic translation, making it a focal point for both therapeutic development and toxicological study (Garreau de Loubresse et al., 2014, Nature).

Other names

Eukaryotic ribosomal A-site80S decoding centerAminoacyl site of the 80S ribosomeRibosomal A-site

Induces translational read-through of premature termination codons by binding to the decoding center and facilitating the incorporation of near-cognate tRNAs, thereby restoring full-length protein production.